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Abstract. The complex network of etiological factors, signals 
and tissue responses involved in chronic prostatitis/chronic 
pelvic pain syndrome (CP/CPPS) cannot be successfully 
targeted by a single therapeutic agent. Multimodal approaches 
to the therapy of CP/CPPS have been and are currently being 
tested, as in the frame of complex diagnostic-therapeutic 
phenotypic approaches such as the urinary, psychosocial, 
organ‑specific, infection, neurological and muscle tenderness 
(UPOINTS) system. In this study, the effect of combination 
therapy on 914 patients diagnosed, phenotyped and treated in 
a single specialized prostatitis clinic was analyzed. Patients 
received α-blockers, Serenoa repens (S. repens) extracts 
combined or not with supplements (lycopene and selenium) 
and, in the presence of documented or highly suspected infec-
tion, antibacterial agents. Combination treatment induced 
marked and significant improvements of National Institutes 
of Health Chronic Prostatitis Symptom Index (NIH-CPSI) 
prostatitis symptom scores, International Index of Erectile 
Function (IIEF) sexual dysfunction scores, urinary peak flow 
rates and bladder voiding efficiency. These improvements, 
assessed after a 6-month course of therapy, were sustained 
throughout a follow-up period of 18 months. A clinically 
appreciable reduction of ≥6 points of the total NIH‑CPSI 
score was achieved in 77.5% of patients subjected to combi-
nation therapy for a period of 6 months. When the patients 
were divided in two cohorts, depending on the diagnosis of 
CP/CPPS [inflammatory (IIIa) vs. non‑inflammatory (IIIb) 
subtypes], significant improvements of all signs and symptoms 
of the syndrome were observed in both cohorts at the end of 
therapy. Intergroup comparison showed that patients affected 
by the IIIa sub-category of CP/CPPS showed more severe 
signs and symptoms (NIH-CPSI total, pain and quality of life 
impact scores, and Qmax) at baseline when compared with IIIb 
patients. However, the improvement of symptoms after therapy 
was significantly more pronounced in IIIa patients when 
compared with IIIb patients. In contrast to current opinion, 
the evidence emerging from the present investigation suggests 
that the inflammatory and non‑inflammatory sub‑categories of 
CP/CPPS may represent two distinct pathological conditions 
or, alternatively, two different stages of the same condi-
tion. In conclusion, a simple protocol based on α-blockers, 
S. repens extracts and supplements and antibacterial agents, 
targeting the urinary, organ specific and infection domains 
of UPOINTS, may induce a clinically appreciable improve-
ment of the signs and symptoms of CP/CPPS in a considerable 
percentage of patients. In patients not responding sufficiently 
to such therapy, second-line agents (antidepressants, anxio-
lytics, muscle relaxants, 5-phosphodiesterase inhibitors and 
others) may be administered in order to achieve a satisfactory 
therapeutic response.
Introduction
Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) 
is a complex condition, characterized by uncertain etiology 
and by limited response to therapy. CP/CPPS affects men of 
all ages, and can significantly impair the quality of life (QoL) 
and the social functioning of patients.
CP/CPPS is characterized by a wide spectrum of symp-
toms, including pain in the pelvic region, irritative and 
obstructive voiding symptoms, ejaculatory pain, sexual 
dysfunction, depression and psycho-social maladjustment 
amongst others (1).
The failure to individuate a single etiological agent has 
hampered the identification of curative interventions for 
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CP/CPPS. It has been hypothesized that infection (occult 
or non-culturable infection included), as well as genetic, 
anatomical, physiological, neurological and immunological 
factors may be involved (alone or combined) in the pathogen-
esis of CP/CPPS. In this regard, experts consider that different 
cases of CP/CPPS are likely to have different etiological 
determinants and different disease progression pathways (2). 
According to Shoskes et al, the etiological determinants of 
CP/CPPS are likely to trigger tissue and cellular responses 
that include inflammation and the upregulation of cytokine 
expression and release. Inflammatory injury may damage 
tissue components such as nerves and blood vessels, in 
turn causing pain that may produce contraction of pelvic 
smooth and skeletal muscles, finally leading to lower urinary 
tract symptoms, ejaculatory pain and pain in other regions, 
including the lower back and abdomen (3). Prolonged pain 
may lead to neurogenic inflammation and peripheral and 
central sensitization.
It is evident that such a complex network of etiological 
factors, signals and cellular responses cannot be successfully 
targeted by a single therapeutic agent. Only in very few cases 
[reviewed in (4)] can a single compound attenuate the symp-
toms of CP/CPPS, and the failure of single-agent therapy was 
denounced as early as in the year 2004 by Nickel et al (5). As a 
consequence, research efforts have been focused on the design 
of new multi-modal therapeutic strategies addressing the wide 
array of CP/CPPS signs and symptoms (6).
In order to design optimal symptom-directed therapeutic 
protocols, the clinical phenotype of each CP/CPPS patient 
should be carefully assessed. A novel algorithm called 
UPOINT (an acronym standing for the urinary, psychosocial, 
organ‑specific, infection, neurological and muscle tenderness 
domains involved in the syndrome) has been validated by a 
number of independent research groups, and is currently 
being tested in daily clinical practice worldwide in its original 
form, or modified to include a sexual dysfunction domain 
(UPOINTS) (7-12).
Following validation of the novel algorithm at the diag-
nostic level, a pilot prospective study focusing on therapy 
demonstrated that a high fraction (84%) of patients treated 
by targeting each positive UPOINT domain had a clinically 
appreciable improvement of CP/CPPS symptoms (7).
Since the year 2000 our research group has adopted a 
multimodal approach to treat CP/CPPS. α-adrenergic receptor 
blockers, antibacterial agents, Serenoa repens extracts and 
various supplements active on the prostate gland have been 
administered to a large number of patients, whose follow-up 
data have been recorded in a database of ~1,600 men affected 
by different forms of prostatitis. The present study was aimed 
at retrospectively evaluating the long-term effect of combina-
tion therapy on CP/CPPS patients, and to attempt a comparison 
with other studies based on UPOINT-driven therapy.
Patients and methods
The present study was performed on patients who were 
subjected to diagnostic and therapeutic protocols routinely 
adopted in our clinical practice (8). Patients provided written 
informed consent to anonymous publication of their clinical 
data. According to the Italian regulations (Determinazione 
AIFA 20/3/2008, GU 76), the protocol describing the present 
observational study was notified to the Ethical Committee of 
the Principal Investigator's hospital (authorization 26/10/2009, 
ICP register: 244).
Diagnostic procedures. The clinical data of 914 fully 
compliant patients, diagnosed in a single urology outpatient 
center specialized in treatment of prostatitis syndromes, and 
meeting a number of selective inclusion criteria were retro-
spectively analyzed. 
Patients between 20-59 years were included in this study 
if they exhibited at a first visit signs and symptoms of cate-
gory III CP/CPPS, according to National Institutes of Health 
(NIH) criteria (NIDDK Chronic Prostatitis Workshop, 1995). 
History collection, clinical, microscopic, microbiological 
and instrumental diagnosis of patients, urological visits as well 
as inclusion/exclusion criteria have been described in detail 
in a previous report of the present study (8), focusing on the 
diagnosis and UPOINTS phenotyping of CP/CPPS patients. 
Urinary peak flow rate (Qmax) and the percentage bladder 
voided volume (%BVV) were assessed in each patient as previ-
ously described (8).
The severity of the chronic prostatitis symptoms was 
scored by means of an Italian validated version of the NIH 
Chronic Prostatitis Symptom Index (NIH-CPSI), addressing 
pain and voiding symptoms, and the impact of the disease 
on patients' QoL (13). A reduction of ≥6 points of the total 
NIH-CPSI score was considered as a clinically appreciable 
improvement of CP/CPPS symptoms (14). All CP/CPPS 
patients were phenotyped according to the UPOINTS system, 
as previously described (8).
The International Index of Erectile Function (IIEF) 
questionnaire was adopted to assess the erectile function of 
patients (15). Mild to severe erectile dysfunction (ED) was 
defined as a sum of the scores for IIEF questions 1‑5 and 15, 
which in total were inferior to 26 (15).
Study design. At time-point V0 (visit zero), after complete 
clinical and microbiological assessments, patients received 
a full course of combination pharmacological therapy. 
Microbiological eradication of pathogens was assessed at 
the end of a 4-week cycle of antibacterial therapy. All other 
tests were performed after 6 months of continuous combina-
tion therapy: at time-point V6 (visit 6 months), patients were 
subjected to a complete diagnostic protocol, including micro-
biological and clinical evaluations. Follow-up visits, including 
instrumental assessments, questionnaires and urological visits, 
were performed 12 months (time-point V12) and 18 months 
(time-point V18) after the start of therapy.
Pharmacological treatment. Starting from time-point V0, 
patients were treated for 6 months with a combination of 
drugs, already tested in a variety of other settings (16).
Combination therapy included a daily dose of the 
α-adrenoceptor blocker alfuzosin (10 mg, extended-release 
formulation; various brands chosen by the patient or general 
practitioner) and a S. repens extract [640 mg/day; from patient 
choice of Permixon® (Pierre-Fabre Pharma, Milan, Italy), 
SABA® (Lampugnani Farmaceutici, Milan, Italy) or Serpens® 
(Laboratorio Italiano Biochimico Farmaceutico Lisapharma, 
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Como, Italy). The latter was administered alone, or in the 
form of a combined tablet preparation (Profluss®; Konpharma, 
Rome, Italy) including S. repens (640 mg/day), lycopene 
(10 mg/day) and selenium (100 µg/day) (17,18).
The patients for which positive microbiological cultures 
of prostate‑specific specimens (expressed prostatic secretions 
and/or post-massage voided urine) were obtained (positive 
UPOINTS infection domain) received in addition an oral 
antibacterial therapy with a fluoroquinolone (ciprofloxacin 
750 mg/day) and a macrolide (azithromycin 500 mg/day, 
the first 3 consecutive days of each treatment week) for 
4 weeks (16).
Statistical analysis of data. Due to the size of the patient popu-
lation, and since the distribution of the NIH-CPSI scores and 
uroflowmetry data in the patient population was normal (not 
shown), the normality assumption was applied to all datasets. 
When ordinal scales were analyzed, both mean and median 
scores were calculated as measures of the central tendency of 
the patient populations, and standard deviations and interquar-
tile ranges are shown as measures of data dispersion.
Intergroup differences were calculated by the 
Mann-Whitney test (questionnaire scales) or the t-test for 
unpaired heteroscedastic samples (continuous variables). 
Intragroup differences were analyzed by a paired t-test 
(continuous variables) or by the Wilcoxon signed-rank test 
(ordinal scales).
When two treatment strategies were compared, the 
analysis of covariance (two-way ANCOVA) was applied to 
analyze inter-arm differences. This test was also applied to 
comparisons of questionnaire scores showing non-skewed 
data distributions, according to Vickers (19). Differences in 
patient proportions at specific study time‑points were analyzed 
by a two-tailed Z test.
The VassarStats on-line statistics platform (http://
vassarstats.net) and the VassarStats ANCOVA Excel spread-
sheet (http://vassarstats.net/exl/ancovaM.xls) were used for 
analysis of data. P<0.05 was considered to indicate a statisti-
cally significant result.
Results
Total patient population. A population of 914 patients, 
meeting the inclusion criteria for the present study, was 
extracted from our clinical database. Patients were affected by 
category III CP/CPPS, of the inflammatory (type IIIa, n=367) 
or non‑inflammatory (type IIIb, n=547) sub‑categories (20). 
Patients were phenotyped according to the UPOINTS 
system (8). Similarly to a preliminary report of the present 
study, and to other international trials (2,8), 57.60, 33.77, 
97.05, 9.94, 46.23, 68.52 and 49.07% of patients exhibited 
a positive urinary, psychosocial, organ‑specific, infection, 
neurological, muscle-tenderness and sexual domain, respec-
tively.
Table I summarizes the clinical findings of the total patient 
population at enrollment (V0), at the end of a 6-month cycle 
of therapy (V6), and 6 or 12 months after the end of therapy 
(time-points V12 and V18, respectively).
Total NIH-CPSI scores decreased significantly from a 
baseline mean value of 20.91 to 9.87 at time-point V6 and 
to 8.15 and 7.62 at time-points V12 and V18, respectively 
(P<0.0001 for all paired comparisons vs. V0, Wilcoxon signed 
rank test). The difference between values at V6 and at V12 or 
V18 was also significant (P<0.0001, Wilcoxon).
Table I. Scores of the NIH‑CPSI and IIEF symptom questionnaires, uroflowmetry data and percentage bladder voided volume in 
the total study population. Data are shown at enrollment (V0), at the end of a 6-month cycle of combination therapy (V6), and at 
follow-up 12 months (V12) and 18 months (V18) after enrollment.
 Study time-point
 --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Variable V0 V6 V12 V18
NIH-CPSI total score 20.91±7.12 (21,10) 9.87±5.71 (9,7)a 8.15±4.52 (8, 4)a,b 7.62±4.13 (8, 4)a,b
[mean ± SD, (median, IQR)]
NIH-CPSI pain score 9.51±3.57 (9,5) 4.08±2.67 (4,2)a 3.35±1.99 (3,1)a,b 3.09±1.86 (3, 2)a,b
[mean ± SD, (median, IQR)]
NIH-CPSI voiding symptom score 4.01±2.59 (4,4) 2.01±1.98 (2,3)a 1.52±1.54 (1,2)a,b 1.45±1.53 (1,2)a,b
[mean ± SD, (median, IQR)]
NIH-CPSI QoL impact score 7.40±2.81 (8,4) 3.82±2.28 (3,2)a 3.23±2.03 (3,2)a,b 3.02±1.77 (3,2)a,b
[mean ± SD, (median, IQR)]
IIEF, items 1-5 and 15 23.05±5.78 (24,9) 26.29±4.18 (28,4)a 26.06±4.92 (28,4)a 26.23±4.61 (28,4)a
[mean ± SD, (median, IQR)]
Urine peak flow rate 14.86±6.50 18.34±5.25c 19.02±4.20c,d 18.89±3.84c
(Qmax, ml/sec) (mean ± SD)
Bladder voided volume (%) (mean ± SD) 84.53±18.63 98.19±7.89c 99.61±4.38c,d 99.57±4.03c
aP<0.0001 vs. V0, Wilcoxon signed rank test. bP<0.0001 vs. V6, Wilcoxon signed rank test. cP<0.0001 vs. V0, paired, two-tailed t-test. dP<0.0001 vs. V6, paired, 
two-tailed t-test. NIH-CPSI, National Institutes of Health Chronic Prostatitis Symptom Index; QoL, quality of life; IIEF, International Index of Erectile Function; 
SD, standard deviation; IQR, interquartile range.
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A clinically appreciable reduction of ≥6 points of the 
NIH-CPSI score (14) was assessed at the end of therapy in 
77.5% of patients (n=708).
A 57% reduction of NIH-CPSI pain scores was calculated 
in this population at the end of therapy. Further significant pain 
reductions were observed at time-points V12 or V18 (Table I).
The distribution of pain severity according to the NIH-CPSI 
pain score cutoffs established by Wagenlehner et al (21) is 
shown in Fig. 1A.
Similar to pain, voiding symptom scores decreased signifi-
cantly at time-point V6, compared with baseline data (Table I). 
An additional attenuation of voiding symptoms was observed 
6 months after the end of treatment (time-point V12), and was 
sustained through the entire follow-up, until the end of the 
study.
The significant improvement of voiding symptoms assessed 
with the NIH‑CPSI was confirmed by instrumental measure-
ment of urinary flow and voiding efficiency; mean peak flow 
rates increased from 14.86 ml/sec at V0 to 18.34 ml/sec at 
V6 and 19.02 or 18.89 ml/sec at V12 or V18, respectively 
(P<0.0001 for all comparisons vs. V0, or V6 vs. V12, paired, 
two-tailed t-test; Table I). Patients' percentage bladder voided 
volume (%BVV), which was 84.53% of total bladder content 
at V0, was also significantly increased at V6 and V12 (98.19% 
and 99.61%, respectively; P<0.0001 for all comparisons vs. V0, 
or V6 vs. V12, paired, two-tailed t-test; Table I); this increase 
was sustained through the entire follow-up, until the end of 
the study. 
Symptom relief, assessed with the NIH-CPSI test, resulted 
in attenuation of the impact of the disease on the QoL of 
patients (Table I).
The IIEF (items 1-5 plus 15) was used to assess ED in the 
study population. A score of 26 was used as a cutoff value to 
evidence mild to severe ED (15). At baseline (time-point V0) 
56.9% of patients showed ED (a score <26). This proportion 
decreased at V6 (26.06%; P<0.0002 vs. V0, two-tailed Z test), 
and remained steady at subsequent time-points (V12, 26.6%; 
V18, 26.4%). Mean IIEF values at V0, V6, V12 and V18, and 
the statistical significance of intragroup comparisons, are 
shown in Table I.
Subgroup analysis based on CP/CPPS sub‑categories (IIIa 
vs. IIIb). The study population included patients affected by 
either the inflammatory (IIIa) or the non‑inflammatory (IIIb) 
sub-categories of CP/CPPS. 
A comparative analysis was performed to assess any 
differential response to therapy between these cohorts. Table II 
summarizes the clinical findings of IIIa and IIIb patient 
cohorts at baseline, at the end of a 6-month cycle of therapy, 
and 6 or 12 months after the end of therapy (time-points V12 
and V18, respectively). Intragroup paired analysis showed that 
both IIIa and IIIb patients underwent significant reductions 
of NIH-CPSI total scores at the end of therapy (P<0.0001 vs. 
V0 for both cohorts, Wilcoxon signed rank test; Table II), 
further improving at the V12 or V18 follow-up time-points 
(P<0.0001 vs. V0 and V6 for both cohorts, Wilcoxon). 
Intragroup analysis of CPSI subscores showed that in 
both IIIa and IIIb patients pain, voiding symptoms and the 
impact of the disease on the QoL decreased markedly and 
significantly at time‑points V6 (P<0.0001 vs. V0 for both IIIa 
and IIIb cohorts, Wilcoxon signed rank test; Table II), and 
decreased further at V12 or V18 (P<0.0001 vs. V0 and V6 for 
both cohorts, Wilcoxon). 
Figure 1B shows the distribution of pain severity scores 
in IIIa and IIIb patients. The two groups showed a marked 
improvement of pain symptoms at 6 months, with no patient 
showing severe pain at this time-point. A small fraction of 
patients had moderate pain symptoms at time-point V6 (IIIa, 
3.73%; IIIb, 8.78%), further decreasing at follow-up (at V12: 
IIIa, 1.86%; IIIb, 1.69%; at V18: IIIa, 2.98%; IIIb, 1.69%).
Uroflowmetry parameters (Qmax and %BVV) improved 
significantly in both groups (P<0.0001 vs. V0 for both IIIa and 
IIIb cohorts, paired t-test; Table II). This effect was sustained 
throughout the follow-up period (Table II). 
Compared with IIEF average baseline values (<26 points 
in both IIIa and IIIb cohorts), at time-point V6 average scores 
Figure 1. Distribution of pain intensity scores, assessed in CP/CPPS patients with the NIH-CPSI. NIH-CPSI sub-scores were assigned to three increasing 
pain levels, according to Wagenlehner et al (21) as follows: Mild pain, 0-7 points; moderate pain, 8-13 points; severe pain, 14-21 points. (A) Pain intensity 
distribution in the total patient population. (B) Pain intensity in patients affected by the inflammatory (IIIa) or non‑inflammatory (IIIb) sub‑categories of 
CP/CPPS.  Data are shown at enrollment (V0), at the end of therapy (V6), and at follow-up time-points (V12, V18). CP/CPPS, chronic prostatitis/chronic pelvic 
pain syndrome; NIH-CPSI, National Institutes of Health Chronic Prostatitis Symptom Index.
  A   B
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were above the 26 point threshold (P<0.0001 vs. V0 for both 
IIIa and IIIb cohorts, Wilcoxon signed rank test; Table II). 
Recovery from ED was sustained throughout the follow-up 
period (Table II).
Intergroup analysis (CP/CPPS IIIa vs. IIIb) showed 
significant differences of baseline values of the NIH‑CPSI 
total score and of pain and QoL subscores, with IIIa patients 
showing more severe symptoms (P<0.001 vs. IIIb for all 
comparisons at time-point V0, Mann-Whitney test; Table II). 
The ANCOVA test was used to analyze differential responses 
to therapy between IIIa and IIIb cohorts, as it corrects baseline 
imbalances and is also suitable for nonparametric analysis of 
data (19). As shown in Table II, analysis of symptom improve-
ment at the end of therapy and follow-up (time-points V6 and 
V12/V18) evidenced significant intergroup differences. At 
time-point V6, pain symptoms improved more markedly in 
IIIa patients (mean reduction, 6.48 points), compared with IIIb 
patients (mean reduction, 4.69 points; P<0.0001, ANCOVA). 
Similarly, voiding symptoms and QoL scores improved more 
markedly in IIIa patients (voiding score mean reduction: IIIa, 
2.5 points; IIIb, 1.63 points; impact on QoL mean reduction: 
IIIa, 4.32 points; IIIb, 3.06 points; P<0.0001 for both compari-
sons, ANCOVA). These differences concurred to generate a 
mean reduction of 13.23 and 9.5 points of the total NIH-CPSI 
score in IIIa and IIIb cohorts, respectively. Also in this case, 
intergroup differences were significant (P<0.0001, ANCOVA). 
A reduction of ≥6 points was observed at the end of therapy in 
88.43% of IIIa patients and in 72.93% of IIIb patients (P<0.001, 
two-tailed Z-test).
Intergroup Qmax values differed at baseline, with IIIa 
patients showing lower peak urinary flows compared with IIIb 
(1.9 ml difference between IIIa and IIIb; P<0.001, unpaired 
t‑test). At time‑point V6, both groups showed a significant 
improvement of mean Qmax values (mean increase: IIIa, 
4.15 ml/sec; IIIb, 3.01 ml/sec), but no intergroup difference 
was determined (P=0.48, ANCOVA). The percentage bladder 
voided volume, which was not different at baseline (P=0.09, 
unpaired t-test), increased more markedly in IIIa patients 
(15.69% increase in mean voided bladder volume), compared 
with IIIb patients (12.28% increase in mean voided bladder 
volume; P<0.001, ANCOVA). 
Analysis of sexual dysfunction (IIEF ED scores) showed 
no baseline imbalances and no intergroup differences at 
time-point V6 (Table II). At baseline, 58.7 and 55.7% of IIIa 
and IIIb patients, respectively, had an IIEF ED score <26. 
These percentages decreased to 24.0% (IIIa) and 27.4% (IIIb) 
at time‑point V6. Intergroup analysis showed no significant 
differences (P=0.6, two‑tailed Z‑test).
Subgroup analyses based on differential treatment
Antibacterial agents. At enrollment, patients were assigned to 
different CP/CPPS cohorts (IIIa vs. IIIb) on the basis of the 
presence/absence of inflammatory findings in post‑massage 
urine or expressed prostatic secretions. However, each study 
arm comprised patients subjected to different protocol treat-
ments. All patients received α-adrenoceptor blockers and 
S. repens extracts. Patients affected by IIIb CP-CPPS not 
showing evidence of infection were not treated with antibacte-
rial agents (NO-AB cohort). Patients with evidence of infection 
(in either the IIIa or IIIb group) were treated with antibacte-
rial agents (AB cohort). In addition, antibacterial therapy was 
administered to patients with inflammatory IIIa CP/CPPS in 
the absence of infection, since the presence of pyuria is often 
suggestive of an underlying occult infection. In this respect, 
experts suggest empirical antibacterial therapy if infection is 
suspected in CP/CPPS patients (22). 
Intergroup analysis limited to pre- and post-therapy data 
was performed to assess any differential response to combi-
nation therapy between the AB and NO-AB cohorts. Total 
NIH-CPSI scores decreased more markedly in the AB cohort 
(mean reduction, 8.51 points) compared with the NON-AB 
cohort (mean reduction, 4.25 points). Comparison by ANCOVA 
evidenced a significant intergroup difference (P=0.027). 
NIH-CPSI pain symptoms and the impact of the disease on 
QoL decreased markedly and significantly at time‑point V6; 
however, intergroup analysis showed no significant differences 
between cohorts (pain, P=0.23; QoL, P=0.81, ANCOVA; data 
not shown). 
NIH-CPSI voiding symptom scores decreased more mark-
edly in the AB cohort (mean reduction, 2.6 points) than in the 
NO-AB cohort (mean reduction, 1.48 points). This intergroup 
difference was highly significant (P<0.0001, ANCOVA). The 
percentage bladder voided volume increase was significantly 
more pronounced in the AB cohort (mean increase, 15.83%) 
compared with the comparator NO-AB cohort (mean increase, 
12.03%; P=0.0029, ANCOVA). Intergroup analysis of pre- and 
post-therapy urinary peak flow rates (AB cohort, 4.25 ml/sec 
increase; NO-AB cohort, 2.83 ml/sec increase) lacked stati-
stical significance (P=0.11, ANCOVA).
Intergroup analysis of IIEF E� scores identifi ed no signifi ‑-
cant differences between cohorts (P=0.48, ANCOVA; data not 
shown).
Phytotherapy and antioxidant supplements. CP/CPPS 
patients were treated with different oral preparations of 
S. repens. One preparation was based on the sole plant extract 
(S cohort), whereas another preparation contained the same 
dose of S. repens extract, combined with lycopene and sele-
nium (SLS cohort). To assess any differential response to the 
two different S. repens preparations, an intergroup comparison 
was performed between the S and SLS cohorts. Patients 
treated with antibacterial agents were not included in this 
subgroup comparison due to their unbalanced presence in the 
S and SLS cohorts; analysis was limited to IIIb patients treated 
with α-adrenoceptor blockers and one of the two alternative 
S. repens preparations. 
In the S and SLS cohorts, combination treatment induced 
a marked and significant improvement of CP/CPPS signs and 
symptoms, assessed at time-point V6 with the NIH/CPSI and 
IIEF questionnaires, or measured by uroflowmetry (Qmax and 
%BVV). 
Intragroup analysis revealed significant reductions of 
NIH-CPSI scores in both groups (P<0.0001 for CPSI total and 
pain, void, and QoL subscores, Wilcoxon signed rank test), 
as well as highly significant improvements of the Qmax and 
%BVV parameters (P<0.0001 for both comparisons, paired 
t-test; data not shown).
Intergroup analysis, limited to pre- and post-therapy data 
(V0 and V6), evidenced that the arm treated with the prepa-
ration of S. repens combined with lycopene and selenium 
showed a significantly improved relief from voiding symptoms, 
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compared with that in patients treated with S. repens alone. 
The mean improvements of voiding scores, assessed with the 
NIH-CPSI test, were 0.72 points for the S cohort and 1.14 points 
for the SLS cohort (P=0.047, ANCOVA). Average increases of 
Qmax at time-point V6 were 1.8 ml/sec in the S cohort and 
2.6 ml/sec in the SLS cohort (P=0.019, ANCOVA). The average 
bladder voided volume increased by 9.2% in the S cohort and 
by 12.9% in the SLS cohort (P=0.011, ANCOVA). 
The mean reduction of the impact of the disease on the 
QoL of patients, assessed with the NIH-CPSI test, was 2.21 
points in the S cohort and 2.66 points in the SLS cohort. This 
differential response was significant (P=0.049, ANCOVA). 
Intergroup analysis showed that the reductions of NIH-CPSI 
pain and total scores were not different at the statistical level 
(data not shown).
Discussion
In a prospective trial by Shoskes et al, it was demonstrated 
that 84% of patients treated with a multimodal therapy 
strategy addressing all six phenotypic domains of UPOINT 
had a reduction of ≥6 points in the total score of the NIH-CPSI 
symptom questionnaire (7). This important result confirmed 
the validity and applicability of the UPOINT algorithm for the 
patient-tailored diagnosis and therapy of CP/CPPS. 
In the present study, a reduction of ≥6 points of the total 
NIH-CPSI score was achieved in 77.5% of patients subjected 
to combination therapy for a period of 6 months. Notably, this 
value is higher than the placebo effect of ~64%, demonstrated 
in long-term studies (23). This result shows that a clinically 
appreciable improvement may be achieved in a considerable 
fraction of patients treated with a fixed combination of agents 
targeting the urinary (α-adrenoceptor blockers and S. repens), 
organ-specific (S. repens, antioxidant/anti-inflammatory 
supplements and anti‑inflammatory macrolides) and infection 
(antibacterial quinolones and macrolides, anti-biofilm and 
immune-modulating macrolides) domains of UPOINTS.
Acknowledging the limitations of a retrospective study 
design, certain comparisons and considerations may be 
attempted.
If an appreciable improvement can be potentially achieved 
in >70% of patients treated with a combination of α-blockers, 
antibacterial agents, plant extracts and supplements, and 
given that drugs targeting the psychological (antidepressants 
and anxiolytics), neurological (amitriptyline and pregabalin) 
and muscle-tenderness domains (myorelaxants) of UPOINTS 
can induce considerable side-effects, it could be advisable to 
design a simple two‑step algorithm for each patient. As a first 
step, a combination similar to the one adopted in the present 
study may be administered. In instances of an unsatisfactory 
response (a reduction of the NIH-CPSI score <6), second-level 
agents such as antidepressants, anxiolytics, pregabalin, myor-
elaxants and others may be added to the therapeutic protocol 
in a second phase.
Phosphodiesterase-5 inhibitors may also be administered 
to patients, to address the sexual dysfunction domain of 
UPOINTS (8,10,12,24). Also in this case, these drugs may 
be administered in instances of failure of first‑line agents, 
since the present study documents that the simple combina-
tion therapy proposed above resulted in an improvement of 
erectile function in approximately half (54.2%) of the patients, 
although phosphodiesterase-5 inhibitors were not adminis-
tered during the present study. Therefore, a therapy initially 
targeting only the U, O and I domains of UPOINTS may in 
turn result in improvements of other domains, such as sexual 
function, in a relevant fraction of patients. This is in agreement 
with the evidence emerging from a previous study focusing on 
chronic bacterial prostatitis, a condition related to CP/CPPS, in 
which it was shown that combination therapy with antibacte-
rial agents, α-blockers and S. repens extracts had a positive 
effect on the sexual function of a substantial proportion of 
patients (16). 
Furthermore, it can be hypothesized that attenuation of the 
symptoms of CP/CPPS and improvement of the sexual func-
tion may have a beneficial effect on the psychological domain 
of UPOINTS, and in particular on disease-related anxiety and 
depression, potentially limiting the administration of psycho-
active drugs to a smaller number of patients. Research is in 
progress to investigate this hypothesis.
The cohort of patients analyzed in the present study 
included subjects affected by the inflammatory (IIIa) and 
non-inflammatory (IIIb) sub-categories of CP/CPPS. This 
sub‑classification has always been controversial, and many 
experts have reputed the IIIa and IIIb variants of CPPS to be 
equivalent if not identical conditions, based on the demonstra-
tion that the presence of leukocytes, and hence the extent of 
inflammation, does not correlate with the severity of symptoms 
of CP/CPPS, and that variable amounts of leukocytes are also 
retrieved in post-massage specimens of healthy/asymptomatic 
subjects (25,26).
In order to explore any difference in the clinical presenta-
tion and in the response to therapy of IIIa and IIIb CP/CPPS, 
subgroup analysis of the patient cohort was performed in the 
present study.
In general, patients affected by the IIIa inflammatory 
sub-category of CP/CPPS exhibited more severe signs and 
symptoms (for example, in NIH-CPSI scores and Qmax) at 
baseline when compared with IIIb patients. However, the 
improvement of symptoms was significantly more pronounced 
in IIIa patients than in IIIb patients. For example, a reduction 
of ≥6 points of the total NIH‑CPSI score (14) was assessed 
at the end of therapy in 88.4 or 72.9% of patients affected by 
CP/CPPS IIIa or IIIb, respectively.
These data are not in agreement with a recent retrospec-
tive Korean study, performed on ~100 subjects, showing no 
baseline imbalances and no differential response to combina-
tion therapy (alfuzosin plus levofloxacin) between IIIa and 
IIIb CP/CPPS patients (27). Although baseline NIH-CPSI 
symptom scores and voiding parameters are almost identical 
between the Korean and the present study, comparison of the 
results is difficult, as in the Korean study therapy courses 
were shorter (6 weeks vs. 6 months in the present study), and 
efficacy assessments were performed at earlier time‑points 
(6 weeks vs. 6 months in the present study).
In contrast to the Korean study and to our own previous 
view, the evidence emerging from the present investiga-
tion suggests that the inflammatory and non‑inflammatory 
sub-categories of CP/CPPS may indeed represent two distinct 
pathological conditions or, alternatively, two different stages 
of the same condition. In the latter case, CP/CPPS IIIb might 
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represent a later stage of the disease, less responsive to treat-
ment, less prone to improvement, and characterized by a less 
pronounced inflammatory profile.
The differential response to therapy between IIIa and IIIb 
cohorts might also be due to the fact that all IIIa patients were 
treated with two combined antibacterial agents, whereas the 
vast majority (>90%) of IIIb patients did not receive antibac-
terial treatment. Antibacterial agents were administered to 
IIIb patients showing evidence of infection, and to all IIIa 
patients. The rationale for administering antibacterial agents 
to non-infected IIIa patients is based on the hypothetical pres-
ence of undetected or difficult‑to‑culture pathogens in prostate 
ducts (22).
In addition to their antibacterial activity, macrolides and, to 
a lesser extent, fluoroquinolones might have concurred to more 
marked symptom improvement in IIIa patients through their 
potent intrinsic anti‑inflammatory properties (28,29).
Although the addition of antibacterial agents to the 
α-blocker/S. repens regime might have concurred to the 
improved response to therapy in IIIa patients, more severe 
symptoms at baseline point to a different clinical presenta-
tion of these patients, compared with subjects affected by the 
non‑inflammatory form of the disease.
To further investigate the impact of antibacterial agents on 
symptom remission, the present study population was divided 
in two cohorts. The cohort treated with antibacterial agents 
included all IIIa subjects, as well as IIIb patients showing 
evidence of infection, whereas the remaining IIIb patients 
received α-blockers and S. repens extracts. Briefly, differen‑-
tial treatment resulted in different intergroup responses. The 
cohort treated with antibacterial agents had a more marked 
improvement of NIH-CPSI voiding and total scores. Voiding 
symptom relief was reflected by a significant improvement 
of peak urinary flow and bladder voiding capacity. This 
result supports the use of antibacterial agents in the frame 
of multimodal treatment of CP/CPPS, although, in contrast 
with published recommendations (22), our clinical group is 
increasingly reluctant to administer antibiotics empirically 
in daily practice, in the absence of documented evidence of 
infection.
CP/CPPS patients were treated over time with different 
oral preparations of S. repens. One kind of preparation, based 
on the sole plant extract, was administered in earlier years in 
our clinical practice. Subsequently, a preparation containing a 
S. repens extract combined with lycopene and selenium was 
adopted, on the basis of published evidence showing increased 
efficacy of this combination (17,18).
The results of the present study suggest that the addition 
of supplements characterized by a marked antioxidant activity 
may contribute to the improvement of voiding symptoms and 
QoL in CP/CPPS patients. These results are in agreement with 
the outcome of two recent randomized trials showing that a 
preparation of S. repens extracts, combined with lycopene 
and selenium, is more active than the plant extract alone as a 
symptom reliever and as a negative modulator of inflammation 
in CP/CPPS patients (18,19).
Within the limits of a retrospective observational study, 
the present results document the efficacy of the multimodal 
administration of diverse agents in the improvement of signs 
and symptoms of CP/CPPS. A reduction of ≥6 points of the 
NIH-CPSI score was achieved in >70% of patients, pheno-
typed with the novel UPOINTS system and treated with a fixed 
combination of α-adrenoceptor blockers, S. repens extracts 
and antioxidant supplements, to which antibacterial agents 
were added, in cases with evidence of prostatic infection or in 
the presence of inflammatory findings strongly suggestive of 
an ongoing occult infective process.
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